KOD at a glance
Kodiak Sciences Inc. (KOD, SEC CIK 1468748) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Kodiak Sciences Inc. (KOD) shares worth $1.6 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by BAKER BROS. ADVISORS LP on November 5, 2026 of 4,703 shares at $98.51 per share.
- In the last 90 days, KOD insiders reported 86 open-market purchases ($181.3M) and 8 open-market sales ($2.7M) on Form 4, a net purchase of $178.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 86 buys · 8 sells
- Net +$178.6M
- 13F holders
- 29 funds
- $1.6B · +1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes identified: risk factors appear substantially carried forward from the 10-K
- Clinical efficacy risk: tarcocimab failed primary non-inferiority endpoints in DAZZLE, GLEAM and GLIMMER
- Regulatory risk: 2024 Loper Bright decision may increase challenges to FDA regulations and create approval uncertainty
- Market risk: Eylea HD gained FDA approval for RVO in November 2025, intensifying retinal-treatment competition
- Supply-chain risk: tarcocimab, KSI-501 and KSI-101 rely on single-source suppliers across China, Japan, UK, US and Switzerland
Management Discussion & Analysis
- No product revenue, compared with no product revenue in the same quarter last year
- Operating loss $67.1M vs $62.4M YoY, net loss $66.2M vs $61.5M
- Worst program trend: KSI-101 expenses $11.7M vs $2.6M, up $9.1M YoY
- Cash $88.7M at September 30, 2026, operating cash used $130.1M through nine months
- $68.9M net ATM proceeds after quarter-end, $280.4M remaining availability; BLA submission planned for Zenkuda in fourth quarter 2026
AI summary of the KOD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Q3 2026 financial results for quarter ended September 30, 2026
- Business highlights accompany the quarterly results
Item EX-99.1: Item EX-99.1
- Zenkuda met DAYBREAK’s primary endpoint with p-value 0.0007, 54% of patients achieving 6-month dosing, supporting planned multi-indication BLA submission in Q4 2026
- Tabirafusp-ted met vision and anatomical endpoints with p-values 0.0036 and <0.0001, while Phase 3 ALTO enrollment advances in diabetic macular edema
Item 8.01: Other Events
- Positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration
- Primary endpoints met for both investigational therapies, supporting potential regulatory submissions
Item EX-99.1: Item EX-99.1
- Zenkuda met DAYBREAK’s primary endpoint with p=0.0007, showing non-inferior vision gains versus aflibercept in wAMD
- 54% of Zenkuda patients reached 24-week dosing at year one under strict treat-to-dryness criteria, supporting differentiated durability
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results and business highlights reported for quarter ended June 30, 2026
- Full financial details and operating developments contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $65.6M, or $1.05 per share, versus $54.3M and $1.03 in Q2 2025
- Cash $125.9M, down from $209.9M at December 31, 2025; management expects funding into 2027
AI summaries of KOD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KOD
Don't miss the next KOD filing
- Alerts as it files. A push when KOD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KOD, by share count.
- Ask anything. An AI agent that reads every KOD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Buy | Nov 5, 2026 | 4,703 | $98.51 |
| BAKER BROS. ADVISORS LP | Buy | Nov 5, 2026 | 81,729 | $98.51 |
| BAKER BROS. ADVISORS LP | Buy | Nov 4, 2026 | 8,742 | $98.51 |
| BAKER BROS. ADVISORS LP | Buy | Nov 4, 2026 | 151,916 | $98.51 |
| Yang Taiyin | M | Oct 23, 2026 | 20,000 | - |
| Yang Taiyin | M | Oct 23, 2026 | 20,000 | $2.35 |
| BORGESON JOHN A. | Sell | Oct 21, 2026 | 8,514 | $87.67 |
| BORGESON JOHN A. | M | Oct 21, 2026 | 30,000 | $2.49 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$277.3M | -$186.8M | -$234.4M |
| Net Income | -$260.5M | -$176.2M | -$230.0M |
| Balance Sheet | |||
| Total Assets | - | $335.6M | $351.5M |
| Equity | $265.8M | $150.3M | $157.4M |
| ROE | -98.0% | -117.2% | -146.1% |
| Per Share | |||
| EPS | $-4.97 | $-3.35 | $-4.32 |
| Cash Flow | |||
| Operating CF | -$154.2M | -$117.3M | -$136.0M |
| CapEx | $41.4M | $375K | $506K |
Source: XBRL data in Kodiak Sciences Inc. (KOD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate KOD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $1.59B |
| Q2 2026 | 28 | $701.5M |
| Q1 2026 | 29 | $612.3M |
| Q4 2025 | 25 | $400.4M |
| Q3 2025 | 25 | $170.3M |
| Q2 2025 | 24 | $37.7M |
| Q1 2025 | 22 | $19.3M |
| Q4 2024 | 18 | $57.0M |
- Citadel Advisors LLC+623.3K (+396%)
- Bank of America Corp+108.4K (+28%)
- JPMorgan Chase & Co+75.8K (+86%)
- Franklin Resources+66.3K (+93%)
- Millennium Management+29.3K (+94%)
- Goldman Sachs Group−325.7K (-14%)
- BlackRock−321.4K (-8%)
- T. Rowe Price Group−315.0K (-10%)
- Two Sigma Investments−279.4K (-59%)
- State Street Corp−190.2K (-8%)
- Ameriprise Financial+57.2K
- Blackstone Group+28.0K
- Principal Financial Group+4.5K
- U.S. Bancorp+73
- FMR LLC (Fidelity)−277.0K
- Allstate−8.4K
- Mangrove Partners−6.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 200 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KOD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Oct 26, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 16, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
KOD SEC filings: frequently asked questions
Are KOD insiders buying or selling?
In the last 90 days, Kodiak Sciences Inc. (KOD) officers, directors and 10% owners reported 86 open-market purchases worth $181.3 million by 1 insider and 8 open-market sales worth $2.7 million by 1 insider on Form 4, a net purchase of $178.6 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold KOD stock?
As of September 30, 2026, the largest Kodiak Sciences Inc. (KOD) holders among the 13F filers tracked by SignalX were BlackRock ($361.6 million), T. Rowe Price Group ($278.1 million), State Street Corp ($211.3 million), Goldman Sachs Group ($188.7 million), Vanguard Capital Management LLC ($168.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did KOD report in its latest 8-K?
Kodiak Sciences Inc. (KOD) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest KOD SEC filings?
Kodiak Sciences Inc. (KOD) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 6, 2026.
What is KOD's SEC CIK number?
Kodiak Sciences Inc. (KOD)'s SEC Central Index Key (CIK) is 1468748. EDGAR lists every KOD filing under that number.
Ask anything about KOD
The research agent reads KOD's filings, financials, insider trades and 13F holders, then answers with sources.